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Summary Imbalances of histone acetyltransferase (HAT)
and deacetylase activity (DAC) that result in deregulated
gene expression are commonly observed in leukemias.
These alterations provide the basis for novel therapeutic
approaches that target the epigenetic mechanisms implicated
in leukemogenesis. As the acetylation status of histones has
been linked to transcriptional regulation of genes involved
particularly in differentiation and apoptosis, DAC inhibitors
(DACi) have attracted considerable attention for treatment of
hematologic malignancies. DACi encompass a structurally
diverse family of compounds that are being explored as single
agentsaswellasincombinationwithchemotherapeuticdrugs,
small molecule inhibitors of signaling pathways and hypo-
methylating agents. While DACi have shown clear evidence
of activity in acute myeloid leukemia, myelodysplastic
syndromes and lymphoid malignancies, their precise role in
treatment of these different entities remain to be elucidated.
Successful development of these compounds as elements of
novel targetedtreatment strategies forleukemia will require that
clinical studies be performed in conjunction with translational
research including efforts to identify predictive biomarkers.
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Histone deacetylases as therapeutic targets
in hematologic malignancies
Among the epigenetic modifications associated with
the development of human cancer, alterations of the
acetylation status of histones play a prominent role
(see [1] for review). The extent of acetylation and
deacetylation on different positions of core histones is
determined by the antagonistic activity of histone
acetylases (HAT) and histone deacetylases (HDAC) and
alters the nucleosomal conformation of both transformed
and non-transformed cells. Deacetylation of histones by
HDACs hinders the accessibility of DNA to transcription
factors that are involved in determining malignant cell
behaviour, thereby changing their activity, subcellular
localisation and interaction partners. In addition,
acetylation is an important post-translational modulation
of a wide range of nuclear and cytoplasmic proteins
involved in the regulation of a multitude of cellular
functions (e.g., p53, tubulin, heat-shock protein 90). A
disrupted equilibrium between HDACs and HATs, with
preponderance of deacetylase activity, leads to transcrip-
tional repression of a diverse set of genes involved in the
regulation of cell proliferation, differentiation and
apoptosis. Aberrant gene trans c r i p t i o nc a u s e db ya b n o r -
mal activity of HATs and HDACs is commonly observed
in leukemia and lymphoma [2–6]. Accordingly, modula-
tion of protein lysine acetylation through inhibition of
histone deacetylases (HDACs) is currently being consid-
ered as an attractive new therapeutic strategy for acute
myeloid and lymphoid leukemias and myelodysplastic
syndromes.
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Aberrant HDAC activity in acute leukemia
In acute myeloid and lymphoid leukemia, recurring
chromosomal translocations result in the generation of
chimeric fusion genes, many of which function as tran-
scriptional regulators. Several of these fusion proteins are
associated with the development of leukemia, partly by
causing transcriptional deregulation of genes responsible
for differentiation and inhibition of apoptosis through
mechanisms linked to chromatin alterations. Binding of
oncogenic transcription factors such as PML-RARα, PLZF-
RARα, AML1-ETO, and others, induce deposition of
aberrant chromatin marks by recruiting histone deacetylases
(HDACs), histone methyltransferases (HMTases), and
DNA methyltransferases (DNMTs) to target genes [7, 8].
Chimeric fusion oncoproteins in leukemia may also
undergo inappropriate forced dimerization [7, 9] which
alters the association between the DNA-binding portion in
the chimeric oncoproteins and their transcriptional co-
factors. This mechanism has been particularly well studied
in the core binding factor leukemias, in which the fusion
proteins resulting from the chromosomal translocations t
(8;21)(q22;q22) (AML1–ETO) and inv(16)(p13q22)
(CBFB–MyH11) act as transcriptional repressors [7, 8].
These fusion proteins are characterized by the disruption of
CBF, a heterodimeric transcription factor that is important
in hematopoietic differentiation. CBF consists of the DNA
binding component, AML1 (also known as RUNX1 or
CBFA2), and CBFB, which stabilizes AML1. Wild-type
AML1 functions as a transcriptional activator. In contrast,
in CBF leukemias the dimerization domains of the partners
of AML1, which include TEL, ETO, and MTG16, repress
the transcription of AML1 target genes by either recruiting
HDACs directly or by recruiting co-repressor-HDAC
complexes such as N-CoR/Sin3/HDAC1 to AML1 respon-
sive promoters. This keeps the associated histones in the
deacetylated state, thereby repressing normal AML1 target
genes involved in differentiation and cell cycle inhibition
[7–11]. AML1–ETO also directly represses transcription of
tumour suppressor genes such as ARF through the AML1
DNA binding domain [12]. HDACs have also been found
in complexes with proteins that regulate cell cycle
checkpoints such as Rb and its family members [13].
Recently, AML1–ETO has also been shown to recruit DNA
methyltransferase 1 (DNMT1) [14] This finding implies
that transcriptional silencing of AML1 target genes occurs
at least partly through an interplay between histone
deacetylation and promoter DNA methylation.
Collectively, these mechanistic insights support the
rationale for developing inhibitors of HDAC activity,
which, by correcting the transcriptional deregulation of
genes involved in cell cycle regulation and apoptosis, could
have therapeutic value.
Disruption of HATs in acute leukemia
In addition to the recruitment of HDACs, DNMTs and co-
repressor complexes, epigenetic deregulation in acute
leukemias and myelodysplastic syndromes also includes a
disruption of HATs by gene mutations or chromosomal
translocations. Two closely related HATs, E1A-associated
300 kDa protein (p300) and the CREB binding protein
(CBP), play distinct but essential roles in hematopoiesis, e.
g. as co-activators for several transcription factors including
p53, pRB, MYB, JUN, FOS, and RUNX1 [15]. CBP/p300
are regarded as functional tumor suppressors, for mice with
inactivated alleles of these gene loci develop hematological
malignancies [16].
Cancer-associated mutations abrogating the enzymatic
activity of HATs have been observed. CBP/p300 are located
on chromosomes 16p13 and 22q13, respectively; regions,
which are frequently lost in tumors [17–19]. In addition,
rearrangement of both genes has been shown in chromo-
somal translocations, resulting in aberrant gain or loss of
acetylation activity. For example, the t(11;16)(q23;p13)
translocation produces mixed lymphcyte leukemia (MLL)-
CBP fusion proteins. Unlike wild-type MLL, these fusion
proteins cause aberrant acetylation at the HOX loci, which
in turn up-regulates the expression of HOX genes and
causes the subsequent development of leukemia. A similar
mechanism may apply to MLL-p300 fusion proteins
derived from the t(11;22)(q23;q13) translocations [11, 15,
20].
The t(8;16)(p11;p13) translocation leads to the pro-
duction of Monocytic leukaemia zinc finger protein
(MOZ)-CBP fusion proteins. MOZ and monocytic
leukemia zinc finger protein-related factor (MORF)
belong to the MYST family of HATs. In normal
hematopoietic cells, MOZ functions as a transcriptional
co-activator to potentiate RUNX1-dependent gene ex-
pression and stimulate cell differentiation. On contrary,
MOZ-CBP fusion proteins down-modulate RUNX1-
dependent gene expression and thus lead to leukemo-
genesis. A similar mechanism may apply to other
chromosomal abnormalities involving MOZ and MORF
genes, such as inversion of chromosome 8 (inv(8))
which fuses the HAT domain of MOZ to the transcrip-
tion factor TIF2 (also known as NCOA2). TIF2 is a
member of the p160 family of nuclear receptor co-
activators known to interact with p300/CBP. MOZ–TIF2
fusion results in the deregulation of transcription
through the aberrant recruitment of CBP to nucleosomal
regions targeted by MOZ [10, 15].
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Transcriptional silencing of genes due to epigenetic
mechanisms is an important alteration in acute lymphoblas-
tic leukemia (ALL), with research so far having focused on
the role of DNA methylation. An exception is the t(12;21)
(p13;q22) (TEL-AML1), which is restricted to precursor B-
cell lineage leukemia and is the most common (~25%)
translocation in childhood acute lymphoblastic leukemia
(ALL). Like AML1 in the CBF acute myeloid leukemias,
the abnormal TEL-AML1 fusion protein can bind to core
enhancer sequences. Instead of activating transcription
through recruitment of co-activators and HATs, it recruits
co-repressors and HDACs. Since TEL-AML1-induced
transcriptional repression was shown to be reversed by
HDAC inhibitors, TEL-AML1-positive ALL may be
considered likely to benefit from treatment with HDAC
inhibitors [21, 22] Preclinical studies testing this hypothesis
are reviewed elsewhere in this paper.
Down-regulation of microRNAs (miRNA) by epigenetic
mechanisms, most notably by DNA methylation, may
contribute to tumorigenesis. A recent study explores the
epigenetic alterations of miRNAs in ALL by analyzing the
methylation and chromatin status of the miR-124a loci in
ALL [23]. Expression of miR-124a was down-regulated in
ALL by hypermethylation of the promoter and histone
modifications including decreased levels of acetylated
histone H3. Epigenetic down-regulation of miR-124a
induced an up-regulation of its target, cyclin-dependent
kinase 6 (CDK6) as well as phosphorylation of retinoblas-
toma (Rb), and contributed to the abnormal proliferation of
ALL cells both in vitro and in vivo. CDK6 inhibition by
inhibition of HDACs decreased ALL cell growth in vitro.
Although an analysis of 353 patients diagnosed with ALL
revealed an association between a higher relapse and
mortality rate and hypermethylation of the tumor suppressor
microRNA Hsa-miR-124a, these results nevertheless pro-
vide the rationale for therapeutic strategies in ALL that either
target the epigenetic regulation of microRNAs and/or
directly target the CDK6-Rb pathway, e.g. by deacetylase
inhibitors.
DAC inhibitors in hematologic malignancies: molecular
targets and biochemical / pharmacologic properties
At present, 18 HDAC isoforms are known which are
grouped into four classes. From a functional as well as from
a translational point of view, class I HDACs (isoforms
1,2,3,8) are the best characterized proteins of this family.
Less extensive information is available on function and
expression of class II isoforms [4–7, 9, 10] while little is
known about class III HDACs (the sirtuins) and HDAC11,
which on the basis of distinct structural properties has been
suggested to constitute an HDAC class on its own.
A large variety of well established as well as novel
HDAC inhibitors possess antineoplastic activity in vitro and
in animal models in vivo. Some of these inhibitors are
unselective, i.e. they target class I and II but not class III,
while others target only specific HDAC classes or isoforms.
As these compounds also inhibit deacetylation of numerous
non-histone proteins, they should preferably be referred to
more broadly as deacetylase inhibitors (DACi). DACi may
be subdivided into two categories, which inhibit nuclear
and cytoplasmic deacetylases, respectively.
The chemical structure of DACi encompasses three
subunits: (1) a zinc-chelating group, (2) a usually hydro-
phobic “spacer” group, and (3) a catalytic domain which
determines the specificity of the compound. DACi
inhibitors are classified by structure and include the
short-chain fatty acids valproic acid and sodium butyrate,
the cyclic tetrapeptides romidepsin (depsipeptide, FK228,
FR901228), Trapoxin A, and Apicidin, the hydroxamic
acids vorinostat (suberoylanilide hydroxamic acid,
SAHA), trichostatin A (TSA), LAQ824, panobinostat
(LBH529) and PXD101, the benzamides MS-275, CI-
994, und MGCD-0103, cyclic tetrapeptides, electrophilic
ketones (trifluoromethylketone), and others (depudecin,
SNDX-275, and isothiocyanates) [4]
Although these DACi differ in structure, potency and
possibly HDAC enzyme selectivity, they target primarily
class I and II HDACs and do not affect the activity of the
class III sirtuins (reviewed by Marchion and Münster [24])
It is becoming increasingly clear that the downstream
effects of HDAC inhibition, which ultimately leads to
growth inhibition and apoptosis in different tumor types,
depend upon both the HDAC inhibitor and the cell type
[25–27]. Only very recently, research began to focus on the
histone acetylation status in human tumours in general and
the specific expression of HDAC isoforms in solid as well
as hematological malignancies.
Non-histone targets of DACi in acute myeloid leukemia
HATs and DACs affect the acetylation status of lysine
residues not only of histones but also of transcription
factors (TF) (eg, p53, E2F1, GATA1, RelA, Y1, MAD/
MAX, TFIIE and TFIIF, and hormone receptors). Altered
acetylation of TFs may affect their DNA binding and
transcriptional activity [4–6, 28]. In addition, DACs have
been shown to deacetylate a multitude of proteins other
than histones or transcription factors, e.g. the cytoskeleton
protein-tubulin, β-catenin, DNA repair enzymes and the
heat shock protein 90 (hsp90) [29–35]. Accordingly,
modulation of DAC function by DACi may not only
affect gene transcription but also modify the stability of
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DNA and other proteins involved in important biologic
functions in the leukemic cells [36]. The sheer number of
transcription factors known to be acetylated suggests that
the acetylation of these nonhistone proteins may have as
much regulatory effect on transcription as the acetylation
of histone proteins. A more comprehensive description of
nonhistone targets of acetylation has been reviewed
recently [36–38].
The molecular basis for the relatively selective antitumor
activity of DACi is unknown. Insigna et al. investigated the
effects of DACis on leukemias expressing PML-RAR or
AML1-ETO [39]. Even though these oncoproteins are
known to initiate leukemogenesis through deregulation of
HDACs, it was shown that oncogene expression is not
sufficient to confer DACi sensitivity to normal cells. DACi-
induced induction of apoptosis in leukemic cells was found
to be p53 independent and depend upon activation of the
death receptor pathway (TRAIL and Fas signaling path-
ways). Interestingly, TRAIL, DR5, FasL and Fas were
upregulated by DACis in the leukemic cells, but not in
normal hematopoietic progenitors, indicating that sensitiv-
ity in leukemias is a property of the fully transformed
phenotype and depends on DACis-induced activation of a
specific death pathway.
DACi-mediated induction of TRAIL was also identified
as a mediator of the selective anticancer action by Nebbioso
et al. [40]. Expression of TRAIL, by directly activating the
TNFSF10 promoter, triggered tumor-selective death signal-
ing in acute myeloid leukemia (AML) cells, without
inducing apoptosis in normal CD34(+) progenitor cells.
DACi induced proliferation arrest, TRAIL-mediated apo-
ptosis and suppression of AML blast clonogenicity oc-
curred irrespective of karyotype.
Heat shock proteins (HSPs) are molecular chaperones
that stabilize folding and conformation of both normal
and oncogenic proteins. These chaperones thereby
prevent the formation of protein aggregates. HSPs are
often overexpressed in human malignancies, including
AML (see [41] for review), and are the main chaperones
required for the stabilization of multiple oncogenic kinases
involved in the development of AML. HSP90 client
proteins are involved in the regulation of apoptosis,
proliferation, autophagy and cell cycle progression;
several of these proteins are considered possible thera-
peutic targets for treatment of AML. The results from
initial phase I/II clinical trials testing HSP90 inhibitors
have documented that HSP90 inhibition can mediate
antileukemic effects in vivo. HSP90 activity is also
regulated by posttranscriptional modulation, and HSP90
inhibition can thereby be indirectly achieved through
increased acetylation caused by DACi (see section
Combination with other agents)
Preclinical studies of DAC inhibitors in acute leukemias
Single-agent DACi in AML
Valproic acid (VPA) has a long history of use as an
antiepileptic drug. After in vitro studies demonstrated that
VPA induced differentiation of carcinoma cells and leukemic
blasts derived from patients with AML, it was discovered
that VPA acts as a DACi [42]. In addition, VPA causes
selective proteasomal degradation of HDAC2, but not of
other class I HDACs (i.e., HDAC 1, 3, and 8) [42].
In t(8;21) acute myeloid leukemia (AML), the AML1/
ETO fusion protein promotes leukemogenesis by recruiting
class I HDAC-containing repressor complex to the promot-
er of AML1 target genes, as described above. VPA disrupts
the physical interaction between AML1/ETO and HDAC1,
stimulates the global dissociation of the AML1/ETO-
HDAC1 complex from the promoter of AML1/ETO target
genes, and induces relocation of both the AML1/ETO and
HDAC1 proteins from the nucleus to a perinuclear region.
Mechanistically, these effects are associated with a signif-
icant inhibition of HDAC activity, histone H3 and H4
hyperacetylation, and recruitment of RNA polymerase II,
resulting in transcriptional reactivation of target genes (i.e.,
IL-3) otherwise silenced by the AML1/ETO fusion protein.
Ultimately, these pharmacological effects resulted in sig-
nificant antileukemic activity mediated by partial cell
differentiation and caspase-dependent apoptosis [43].
VPA was recently shown to enhance proliferation and
self-renewal of normal hematopoietic stem cells, raising the
possibility that VPA may also support growth of leukemic
progenitor cells (LPC). Indeed, VPA maintained a signifi-
cantly higher proportion of CD34(+) LPC and colony
forming units compared to control cultures in six AML
samples, but selectively reduced leukemic cell numbers in
another AML sample with expression of AML1/ETO.
These data suggest a differential effect of VPA on the
small population of AML progenitor cells and the bulk of
aberrantly differentiated blasts in the majority of AML
samples tested [44].
The new hydroxamic acid derivative, ITF2357, blocked
proliferation and induced apoptosis in AML1/ETO-positive
Kasumi-1 and primary blast cells in concentration of
0.1 μM, whereas AML1/ETO-negative HL60, THP1 and
NB4 cell lines were sensitive only to 1 μM ITF2357. In
Kasumi-1 cells, ITF2357 induced AML1/ETO degradation
through a caspase-dependent mechanism and also deter-
mined DNMT1 efflux from, and p300 influx to, the
nucleus. Moreover, ITF2357 induced local H4 acetylation
and release of DNMT1, HDAC1 and AML1/ETO, paral-
leled by recruitment of p300 to the IL-3 gene promoter.
ITF2357 treatment, however, did not induce re-expression
of IL-3 gene. Accordingly, the methylation level of IL-3
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As VPA and ITF2357 seem to specifically target AML1/
ETO-driven leukemogenesis, integration of both class I-
selective and pan-DACi in novel therapeutic approaches for
AML1/ETO-positive AML may be worthwhile.
Single-agent DACi in acute lymphoblastic leukemia
The potential anti-leukemic activity of DACi in ALL has
been examined in a small number of preclinical studies;
most of these tested DACi as a single agent in vitro using
human ALL cell lines as models.
An early study compared the in vitro effects of the cyclic
tetrapeptide romidepsin (FK228) on human leukemia/
lymphoma cells and cell lines with normal hematopoietic
cells [46]. Romidepsin induced G1 arrest and / or apoptotic
cell death at nanomolar concentrations. Clinical samples
from patients with ALL were more sensitive to romidepsin
at clinically achievable drug concentrations than either
normal peripheral blood or bone marrow mononuclear cells
or normal progenitor cells. Expression levels of HDAC-1
and HDAC-3 proteins did not correlate with the sensitivity
to romidepsin.
The anti-leukemic activity and mode of action of the
hydroxamic acid derivative, LAQ824 was studied using
four human pre-B lymphoblastic cell lines as models
representing different cytogenetic subsets (Sup-B15 and
TMD-5, both t(9;22) positive, SEM, t(4;11) positive, and
NALM-6 cells). LAQ824 significantly inhibited the prolif-
eration of leukemic lymphoblastic cell lines; this was due to
increased apoptosis accompanied by activation of caspase-3
and caspase-9, cleavage of poly(ADP-ribose)-polymerase
(PARP) as well as by down-regulation of Bcl-2 and
disruption of the mitochondrial membrane potential. Sur-
prisingly, LAQ824-induced apoptosis was partially inde-
pendent of caspase activation [47].
Panobinostat (LBH589), a broad-spectrum DACi closely
related to the hydroxamate LAQ824 but with more favorable
pharmacologic properties, potently induced cell-cycle arrest,
apoptosis, and histone (H3K9 and H4K8) hyperacetylation in
two human cell line models of Philadelphia chromosome-
negative acute lymphoblastic leukemia (T-cell MOLT-4 and
pre-B-cell Reh). Panobinostat treatment increased mRNA
levels of proapoptosis-, growth arrest-, and DNA damage
repair genes including FANCG, FOXO3A, GADD45A, and
GADD45B. This was associated with increased histone
acetylation at the GADD45G promoter and phosphorylation
of histone H2AX. Treatment with panobinostat also induced
apoptosis in primary ALL cells, including those from a
relapsed patient [48].
A comparison of the growth inhibitory and apoptotic
activity of several DACi’s that differ in their subclass
selectivity towards glucocorticoid sensitive and resistant
acute lymphoblastic leukemia cells (ALL) and patient blasts
was reported by Tsapis et al. [49]. Vorinostat (SAHA)
displayed similar efficacy on glucocorticoid-sensitive and
insensitive ALL cells but did not synergize with dexameth-
asone. Both B-precursor and T-ALL cells were much more
efficiently killed by VPA and by the pan-DACi vorinostat
than by the sub-class I selective DAC inhibitor MS275.
This group´s previous observation that MS275 and vorino-
stat displayed a similar growth inhibitory and proapoptotic
activity in the AML cell line U937 suggest that cellular
context may be an important determinant of the biologic
response to DACi. The mechanisms of vorinostat-induced
apoptosis in ALL likewise were cell-line dependent, acting
through initiator caspase 10 in CEM-C7 cells while
inducing apoptosis through the intrinsic, as well as through
caspase-independent death pathways in CEM-C1 cells. In
addition, vorinostat induced re-expression of DR5 in
glucocorticoid-insensitive CEM-C1 cells that do not ex-
press DR5 and are insensitive to TRAIL, indicating that
vorinostat may overcome glucocorticoid resistance by
inducing alternative death pathways. This ability of
DACi to induce apoptosis in glucocorticoid-resistant
ALL was confirmed in a more recent report [49]. Taken
together, these studies establish that several DACi possess
potent growth inhibitory activity against B-precursor and
T-cell ALL largely independent of specific cytogenetic
aberrations such as TEL-AML1 [50]. Anti-leukemic
activity is associated with up-regulation of genes critical
for DNA damage response andg r o w t ha r r e s t .T h e s e
findings are not restricted to the in vitro setting, as DACi
have demonstrated potent antitumor activity in two NOD/
SCID mouse models of B-cell precursor childhood ALL
[51].
Combination of DACi with differentiation-inducing agents
in AML and MDS
Treatment with DACi’s alone or in combination with either
all-trans retinoic acid (ATRA) or granulocyte colony-
stimulating factor is able to overcome inhibition of
differentiation caused by chimeric fusion oncoproteins such
as PMLRARα, PLZF-RARα, or AML-ETO [5, 52–55]. In
addition, combination of DACi’s with ATRA induces
differentiation of APL cells that are resistant to treatment
with ATRA alone [54]. Recently, primary leukemia blasts
were shown to undergo differentiation following treatment
with a combination of ATRA and DACi’s[ 42, 55].
Combination with hypomethylating agents
Functionally, histone acetylation and DNA methylation are
tightly linked. For example, DNA methyltransferases
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chromatin B-precursor and T-cell with repressed genes and
thereby augment gene repression. Since DNA methylation
is the principal mechanism for suppressing gene expression,
methylated genes are typically resistant to treatment with
DACi alone. However, sequential exposure of malignant
cells with a DNMT-inhibitor followed by a DACi had
synergistic effects on reactivation of gene expression and
induction of apoptosis [56, 57].
The anti-apoptotic transcription factor NFkappaB is
constitutively activated in myeloblasts arising in high-risk
myelodysplastic syndromes (MDS) and AML. Recent
studies indicate that DNMT inhibitors (such as azacytidine
and decitabine) and DACi (such as trichostatin A and VPA)
can inhibit the constitutive activation of NFkappaB in
malignant myeloblasts in vitro and in vivo. The rapid onset
of this effect within a few hours suggested that it was not
due to epigenetic reprogramming; indeed, DNMT and
HDAC inhibitors reduced the phosphorylation of the
NFkappaB-activating kinase IKKα/ß. Thus, inhibition of
NFkappaB and IKKα/ß by DNMT inhibitors in concert
with DACi may contribute to the antileukemic activity of
these classes of agents [58].
Combined treatment with panobinostat and decitabine
may potentiate antileukemia activity against human AML
cells by other mechanisms as well. The histone methyl-
transferase EZH2 modulates DNA methylation by recruit-
ing DNMT1 to the DNA. Exposure to the pan-DACi
panobinostat reduces DNMT1 and EZH2 protein levels by
inhibiting the chaperone association of Hsp90 with
DNMT1 and EZH2. This promotes their proteasomal
degradation and disrupts the interaction of DNMT1 with
EZH2. In K562 myeloid leukemia cells, co-treatment with
panobinostat and decitabine caused greater diminution of
DNMT1 and EZH2 levels than either agent alone. Exposure
to panobinostat and decitabine in combination augmented
induction of apoptosis of primary AML but not normal
CD34(+) bone marrow progenitor cells and may thus exerts
clinically relevant antileukemia activity against human
AML cells [59].
Combination of DACi with chemotherapy
Molecular perturbations resulting from exposure to DACi
lower the threshold for apoptosis by multiple mechanisms.
This supports the rationale for combining DACi with
conventional cytotoxic agents, which generally trigger
apoptosis by perturbing cell cycle and/or inducing DNA
damage [28]. Additional support for this basic concept
stems from studies in solid tumors, demonstrating that co-
treatment with DACi, e.g. vorinostat or LAQ824, signifi-
cantly enhances the cytotoxic effects of docetaxel, epothi-
lone B, and gemcitabine against human breast cancer cells
[34], of fluorouracil against colorectal cancer and of
etoposide, camptothecin, doxorubicin, and cisplatinum
against glioblastoma cells [60, 61]. Co-treatment with
phenylbutyrate has also been documented to increase
the activity of conventional chemotherapeutic agents
commonly used in treatment of acute leukemias such
as cytarabine and etoposide, against non-Hodgkin’s
lymphoma, chronic lymphoid leukemia (CLL), and multiple
myeloma cells [62, 63].
The potential value of combining DACi with top-
oisomerase II-inhibitors is based on preclinical studies
suggesting a DACi-mediated stimulation of the enzyme in
human leukemic cells [64, 65]. Anthracyclines induce DNA
double strand breaks by forming a complex with both the
DNA and the DNA repair enzyme topoisomerase II, which
disrupts DNA replication and transcription [66].
The pan-DACi panobinostat was tested in combination
with doxorubicin on AML cell lines and primary leukemia
blasts and induced cell death by an increase in the
mitochondrial outer membrane permeability and release of
cytochrome c from the mitochondria, resulting in caspase-
dependent apoptosis accompanied by upregulation of Bax,
Bak and Bad. The drug combination provoked a strong
activation of a DNA damage response, indicating that this
combination may trigger cell death by a mechanism that
induces DNA double-strand breaks [67]. These data are
consistent with a report by Sanchez et al, which showed
that simultaneous exposure of AML cells to idarubicin and
VPA or vorinostat in vitro led to a significant and
synergistic increase in the proportion of apoptotic cells
[66]. Taken together, these data indicate that the combina-
tion of panobinostat and an anthracycline may be an
effective therapy for the treatment of AML.
Apart from anthracyclines, cytosine arabinoside (ara-C)
and etoposide are the most widely used chemotherapeutic
agents for treatment of AML. The DACi vorinostat was
shown to induce topoisomerase II expression and sensitize
human leukemia cells to etoposide and other inhibitors of
topoisomerase II [65]. The combination of etoposide or ara-
C with vorinostat was evaluated in a preclinical study using
cell proliferation assays and cell cycle analysis to determine
the effects on HL-60 myeloid leukemia cells and K562
myeloid blast crisis chronic myelogenous leukemia cells.
The sequence of drugs proved to be important: cytotoxic
antagonism resulted when vorinostat was combined con-
comitantly with ara-C, whereas the sequential administra-
tion with vorinostat given prior a drug-free interval
followed by ara-C was mostly synergistic. Etoposide
combined with vorinostat was additive to synergistic, and
the synergism became more pronounced when etoposide
was given after vorinostat. Cell cycle analyses revealed that
the sequence-dependent interaction of vorinostat and ara-C
or etoposide reflected the arrest of cells in G1 or G2 phase
Invest New Drugs (2010) 28 (Suppl 1):S36–S49 S41during vorinostat treatment and recovery into S phase after
removal of vorinostat [68].
Interactions between the novel benzamide DACi MS-
275 and fludarabine were examined in lymphoid and
myeloid leukemia cells in relation to mitochondrial injury,
signal transduction events, and apoptosis. Prior exposure of
Jurkat lymphoblastic leukemia cells to a marginally toxic
concentration of MS-275 for 24 hours sharply increased
mitochondrial injury, caspase activation, and apoptosis in
response to a minimally toxic concentration of fludarabine,
resulting in highly synergistic antileukemic interactions and
loss of clonogenic survival. Simultaneous exposure to MS-
275 and fludarabine also led to synergistic effects, but these
were not as pronounced as observed with sequential
treatment. Similar interactions were noted with myeloid
cell lines, other DACi (e.g., sodium butyrate) and other
nucleoside analogues (gemcitabine). Potentiation of fludar-
abine lethality by MS-275 was associated with acetylation
of histones H3 and H4, down-regulation of the antiapop-
totic proteins XIAP and Mcl-1, enhanced cytosolic release
of proapoptotic mitochondrial proteins (e.g., cytochrome c,
Smac/DIABLO, and apoptosis-inducing factor), and cas-
pase activation. It was also accompanied by the caspase-
dependent down-regulation of p27, cyclins A, E, and D1,
and diminished phosphorylation of retinoblastoma protein.
Combined exposure of cells to MS-275 and fludarabine
was associated with a significant increase in generation of
reactive oxygen species (ROS); moreover, both the increase
in ROS and apoptosis were largely attenuated by coadmin-
istration of the free radical scavenger L-N-acetylcysteine
[69].
The drugs used in ALL-specific regimens differ consid-
erably from those employed in treatment of AML. The
antifolate methotrexate (MTX), a universal component of
ALL therapies, is metabolized by folylpoly-gamma-
glutamate synthetase (FPGS) into long-chain polygluta-
mates (MTX-PG(3-7)), resulting in enhanced cytotoxicity
from prolonged inhibition of dihydrofolate reductase
(DHFR) and thymidylate synthetase (TS). Identification of
a hypersensitive site upstream from exon-1 of the FPGS
gene suggested that chromatin remodeling could alter
FPGS expression. Leclerc et al. demonstrated that HDAC1
is recruited by NFY and Sp1 transcription factors to the
FPGS promoter in ALL cell lines. Exposure of these cell
lines to the DACi´s sodium butyrate and vorinostat
increased FPGS mRNA expression by 2- to 5-fold,
whereas DHFR and TS mRNA expression was decreased.
Combination treatment with MTX plus vorinostat signif-
icantly enhanced cytotoxicity and apoptosis in B- and T-
ALL cell lines as compared with each drug alone.
Vorinostat lead to the intracellular accumulation of long-
chain MTX-PG(3-7). Therefore, DACi-induced FPGS
expression increases the accumulation of MTX-PG(3-7)
and cytotoxicity in ALL cell lines, which is potentiated by
DHFR and TS downregulation [70].
Taken together, the findings indicate that DACi induces
multiple perturbations in signal transduction, survival, and
cell cycle regulatory pathways that lower the threshold for
chemotherapy-mediated mitochondrial injury and apoptosis
in human myeloid and lymphoid leukemia cells. These data
also provide insights into possible mechanisms by which
novel, clinically relevant DACi might be used to enhance
the antileukemic activity of a wide spectrum of standard
chemotherapeutic agents, including anthracyclines, nucleo-
side analogues such as fludarabine, topoisomerase inhib-
itors and antimetabolites. While these observations suggest
that the combination of DACi and cytotoxic drugs may
enhance the efficacy of therapy for AML and ALL, there is
evidence that the sequence of drug administration may be
of paramount importance, and that inattention to proper
scheduling of these agents may even be antagonistic.
Furthermore, the effect of combination treatment on non-
hematologic organ toxicity is unknown. Other caveats
include the possibility of drug-drug interactions and the
theoretic potential of DACi´s to induce drug resistance by a
variety of mechanisms, as will be discussed below (see
section “DACi—associated drug resistance”). Ultimately,
well-controlled phase I and II studies will be necessary to
determine the feasibility and clinical utility of these
promising strategies.
Combination with other agents
Chimeric oncoproteins with constitutive tyrosine kinase
activity such as BCR-ABL and mutant receptor tyrosine
kinases such as mutant fms-like tyrosine kinase 3 (FLT3)
contribute to the leukemic phenotype in a variety of acute
and chronic leukemias and are therefore targeted clinically
by selective inhibitors of the respective tyrosine kinases. In
addition, these aberrant kinases are client proteins of the
molecular chaperone heat shock protein 90, raising the
possibility that inhibition of HSP90 could lead to depletion
of these oncogenic proteins and act synergistically with
TKIs in mediating anti-leukemic effects. The pan-DACi
LAQ824 induces acetylation and inhibition of HSP90.
When biphenotypic leukemia MV4-11 cells were treated
with LAQ824, levels of FLT-3 and p-FLT-3 were attenuated
due to enhanced proteasomal degradation of these kinases.
Cotreatment with LAQ824 and PKC412 synergistically
induced apoptosis of MV4-11 cells and enhanced apoptosis
of primary AML cells expressing mutant FLT-3. These data
support the notion that the combination of LAQ824 and
PKC412 is highly active against human AML cells with
mutant FLT-3 [71].
The effect of the DACi MS-275 against a variety of
human leukemia cells with defined genetic alterations was
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arrest of MOLM13 and MV4-11 AML cells, which possess
internal tandem duplication mutation in the FLT3 gene
(FLT3-ITD). Exposure of these cells to MS-275 decreased
levels of total, as well as, phosphorylated forms of FLT3,
resulting in inactivation of its downstream signal pathways,
including Akt, ERK, and STAT5. Further studies found that
MS-275 induced acetylation of Hsp90 in conjunction with
ubiquitination of FLT3, leading to degradation of FLT3
proteins in these cells. The action of MS-275 in leukemia
cells was potentiated by inhibition of MEK/ERK signaling,
suggesting that DAC inhibition may be useful for treatment
of individuals with leukemia possessing activating mutation
of FLT3 gene.
An analogous experimental approach was taken in a
study investigating the effect of MS-275 in combination
with pharmacological blockage of Akt/mammalian target of
rapamycin (mTOR) signaling in HL60 AML and NB4
acute promyelocytic leukemia (APL) cells [72]. Inactiva-
tion of mTOR by the rapamycin analog RAD001 (ever-
olimus) significantly enhanced MS-275-mediated growth
inhibition and apoptosis of these cells. When used in
combination, RAD001 potentiated the ability of MS-275 to
induce differentiation of HL60 and NB4 cells. Proliferation
of HL60 tumor xenografts in nude mice was significantly
inhibited by combining RAD001 with MS-275, without
adverse effects. Taken together, concomitant administration
of a DACi and an mTOR inhibitor may be a promising
treatment strategy for the individuals with a subset of
human leukemia.
Although VPA is a less potent DACi than the hydroxa-
mic acid or benzamide derivatives, strong anti-proliferative
and pro-apoptotic effects of VPA were observed on human
ALL and CML cell lines at concentrations achievable in
vivo. These effects were most pronounced in ALL cell lines
as well as in primary ALL cells. Notably, VPA revealed
enhanced activity with imatinib mesylate, nilotinib, the
farnesyl transferase inhibitor SCH66336, interferon-alpha
and cytosine arabinoside. VPA inhibited the growth of
colony-forming cells from 12 Ph + chronic-phase CML
patients, but also of those from normal healthy controls in a
dose-dependent fashion. In conclusion, VPA, whether alone
or in combination with other non-classical anti-leukemic
compounds, exerts significant anti-leukemic effects on
human ALL and CML cells [73].
The proteasome has been successfully targeted for the
treatment of multiple myeloma and mantle cell lymphoma,
but proteasome inhibition alone has been clinically less
effective in other hematologic malignancies. In leukemic
cell lines, the novel proteasome inhibitor NPI-0052 and
DACi synergistically induced apoptosis in leukemia cells
in a caspase-8- and oxidant-dependent manner. In leuke-
mic mice, treatment with NPI-0052 reduced the white
blood cell (WBC) burden over 35 days. The combination
of NPI-0052 with the DACi MS-275 or valproic acid was
more effective than the combination of bortezomib with
these DACi’s[ 74]. Further studies aimed at identifying
mechanisms of synergy revealed that NPI-0052 elicits
caspase-8 and oxidative stress-dependent epigenetic alter-
ations, and that DAC inhibition repressed expression of
the proteasomal beta5, beta2, and beta1 subunits, conse-
quently inhibiting respective enzymatic activities. These
results indicate that crosstalk between NPI-0052 and
DACi contributes to the synergistic cytotoxic effect on
leukemia cells. This reinforces the potential clinical utility
of combination studies of DACi and proteasome inhibitors
[75].
Clinical experience with deacetylase inhibitors in MDS
and AML
To date, clinical examination of DACi in patients with
AML has met with limited success. Current experience is
mostly restricted to phase I or phase II studies involving
small numbers of patients.
Valproic acid is the only DACi that has been clinically
investigated in larger numbers of patients with MDS. An early
clinical trial involving 18 MDS patients showed an overall
response rate of 37% (1 partial response (PR) and 6
hematologic improvements (HI)). All-trans retinoic acid
(ATRA) did not enhance the clinical activity in patients
who had not already demonstrated a response to VPA [76]. In
a subsequent report of 43 patients with MDS, the overall
response rate was 35% (1 PR, and 15 HI) [77]. Efficacy of
the VPA +/- ATRA treatment seems to be inversely correlated
with the stage of the disease. According to Kuendgen et al.,
low or intermediate-I IPSS scores or a normal bone marrow
blast count proved to be good predictors for response [78].
The combination of VPA with ATRA was also tested in
AML patients who were considered ineligible for intensive
chemotherapy. A disappointingly low response rate of only
5% with no CR was observed among 40 patients receiving
this combination [79] Similarly, none of 26 patients with
high-risk AML achieved a CR in another study examining
combined treatment with VPA and ATRA [80]. Results did
not improve when ATRA was added later on in another
pilot study with 8 AML patients [81]. Nevertheless, 5 out of
11 patients with de novo AML responded to a therapy with
VPA, ATRA and theophylline (1 CR, 2 complete remis-
sions with incomplete recovery of peripheral blood counts
(CRi), 2 HI) [82].
In view of the development of the novel, considerably
more potent DAC inhibitors vorinostat, panobinostat,
romidepsin and the isotype-specific MGCD0103, the use
of VPA in patients with AML, as a single agent or in
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The role of VPA in combination with hypomethylating
agents will be addressed in a later section of this review.
Vorinostat was investigated as a single agent in a phase I
study with 31 AML and 10 MDS patients. The maximal
tolerated dose was 200 mg BID. Seven patients experienced
hematologic improvement, including 4 CR in patients with
AML. Increased histone acetylation was observed at all
dose levels [83]. These favorable results were not con-
firmed in a randomized phase II trial, in which only one out
of 37 AML patients achieved CR [84].
Panobinostat (LBH589) was administered in a phase I
study as a 30-min infusion on days 1 to 7 of a 21-day cycle.
Fifteen patients with AML (n=13), ALL (n=1), or MDS
(n=1) were treated. At doses <11.5 mg/m
2, i.v. panobino-
stat was well tolerated with consistent, albeit transient
antileukemic and biologic effects: in 8 of 11 patients
peripheral blasts declined, but rebounded following the 7-
day treatment period. The median acetylation of histones
H2B and H3 in CD34(+) and CD19(+) cells increased
significantly during therapy, as did apoptosis in CD14(+)
cells [85]. Oral panobinostat was evaluated in patients with
advanced hematologic malignancies. Doses of ≥ 40 mg
weekly lead to 2 CRs out of 26 evaluable AML patients [86].
Romidepsin is a potent, bicyclic tetrapeptide with
DAC-inhibitory activity. Twenty patients with AML were
treated at 13 mg/m(2)/d on days 1, 8, and 15 of a 28-day
cycle. Antileukemic activity was observed in 5 of 7
patients with chromosomal abnormalities known to recruit
HDACs, including those involving core binding factor
(CBF). Two patients had clearance of bone marrow blasts
and 3 patients had a greater than 50% decrease in bone
marrow blasts. These responses were associated with a
significant increase in MDR1, p15 and p14 expression
[87]. In a phase II study in patients with high-risk MDS
and AML, one patient achieved a CR, 6 patients
experienced stable disease [88].
The hydroxamate DACi belinostat was administered as a
30-min i.v. infusion on days 1-5 of a 21-d cycle to 16
patients with advanced hematologic malignancies. No
complete or partial remissions were noted in these heavily
pre-treated patients [89].
In contrast to the potent pan-DACi panobinstat, belino-
stat and vorinostat, the orally administered benzamide
MGCD0103 is a selective inhibitor of HDAC1, 2, 3 (class
1) and 11 (class 4) and does not inhibit class 2 HDACs. In a
phase I study, 3 of 29 patients with leukemia or MDS
achieved a CR [90].
A phase I dose escalation study of the synthetic
benzamide derivative MS-275 was completed in 75 patients
with advanced acute leukemias. In spite of biologic
alterations such as increase in protein and histone H3/H4
acetylation, p21 expression, and caspase-3 activation in
bone marrow mononuclear cells, no clinical responses were
seen [91].
Toxicity of deacetylase inhibitors
The most frequently adverse effects observed during DACi
treatment for hematologic malignancies include gastroin-
testinal toxicity with nausea, vomiting and diarrhea, as well
as fatigue, thrombocytopenia, neutropenia and non-specific
ECG changes such as flattened T-waves, ST-segment
depression, and QT-prolongation [92].
These changes are dose-dependent and represent a class
effect of DACi. The pathogenesis of thrombocytopenia is
unclear, but does not appear to involve cytotoxic mecha-
nisms, as they are reversible within a few days of drug
discontinuation. The other adverse events typically also
rapidly revert to normal, or are easily controlled by prompt
institution of supportive therapy, e.g. in the case of diarrhea.
Nevertheless, the different DACi display some notable
differences regarding their toxicity profiles.
Epigenetic therapy combining deacetylase-
and DNA-methyltransferase-inhibitors and/or ATRA
in AML and MDS
The first clinical studies to combine DACi and hypome-
thylating agents in patients with MDS and AML were
conducted with VPA (see Table 1). Promising results were
obtained in each of these studies [93–96] indicating both
improved and accelerated responses with combined epige-
netic therapy: the time to response was significantly shorter
with combined therapy (1–3 cycles) than with single-agent
DNMT (4–6 cycles). VPA was targeted to therapeutic
plasma levels of at least 50 μg/mL to increase the efficacy
of the hypomethylating agent [96], but no association
between histone acetylation and response was observed
[97]. Further correlative studies demonstrated reversal of
p15 or CDH-1 promoter methylation during the first cycle
of therapy in all six responding patients, whereas no
demethylation was observed in any of the six non-
responders [97].
Even though these trials were designed primarily as
dose-finding studies, the 20–30% remission rate (CR and
CRi) was higher than generally observed with 5-azacitidine
or decitabine when used as a single agent. This also holds
true for a combination trial of SAHA and decitabine: of 61
patients evaluable for response, a CR or CRi was achieved
by 18% patients with MDS, 8% with relapsed/refractory
AML, and 36% with untreated AML. [98] Even higher CR/
CRi rates of up to 40 to 60% were achieved in untreated
patients with AML by combining a hypomethylating agent
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revealed that responders received more cycles of therapy
and had significantly longer survival. Non-responding
patients had a higher WBC and higher bone marrow blast
count at the start of therapy. In general, patients who relapse
after combination epigenetic therapy appeared to have a
poor prognosis [99].
Numerous further combination studies using potent
HDACi are currently being conducted, the results of which
are being awaited with interest.
Combination of deacetylase inhibitors with cytotoxic
agents
The rationale for phase I trials of the sequential combina-
tion of vorinostat followed by cytotoxic agents in patients
with acute leukemias stems from in vitro studies showing
that the sequence-dependent interaction of vorinostat and
cytarabine or etoposide arrested the cells in G1 or G2 phase
during vorinostat treatment and allowed recovery into S
phase after removal of vorinostat [68]. Concurrent admin-
istration of vorinostat and idarubicin for 3 days was
demonstrated in a phase I trial in 41 patients with refractory
leukaemia (90% AML), with 2 CRs, 1 CRi and 4 marrow
responses. Correlative studies demonstrated histone acety-
lation in patients on therapy and modulation of CDKN1A
and TOP2A (topoisomerase II) gene expression and a dose-
related elevation in plasma vorinostat concentrations [100].
Preliminary results of a phase II study of vorinostat
followed by idarubicin and cytarabine with 45 mostly high-
risk AML patients aged > 65 years were reported. Induction
therapy consisted of oral vorinostat 500 mg TID (days 1 to
3), idarubicin 12 mg/m
2 iv (days 4 to 6) and cytarabine
(1.5 g/m
2 as a continuous infusion on days 4 to 7) followed
by a maximum of 5 consolidation cycles with dose-reduced
chemotherapy. Complete remission (CR) after one course
of therapy was achieved in 35 patients and 1 patient
achieved a CRi for an overall response rate of 80%. No
excess toxicity with the addition of vorinostat has been
observed compared to standard induction therapy [101].
DACi-associated drug resistance
The rationale for developing deacetylase inhibitors as anti-
leukemic agents is based on evidence showing induction of
cellular differentiation, growth arrest, and apoptosis of
malignant cells, but there is no evidence that only genes
involved in leukemogenesis are targeted by DACi. Recent
reports indicate that expression of the multidrug resistance-
1 (MDR1) gene is also regulated by epigenetic mecha-
nisms, raising the possibility that this and other drug
transporters able to counteract the cytotoxicity of various
anti-leukemic drugs may be upregulated by DACi. This
was in fact shown to be the case in a recent in vitro study
demonstrating that in AML cells, expression of MDR1,
breast cancer resistance protein (BCRP), and multidrug
resistance-associated proteins (MRP) 7 and 8 were induced
by phenylbutyrate, valproate, vorinostat or trichostatin A in
a dose- and time-dependent manner. The pattern of gene
induction by different DACi was shown to be cell line
specific and associated with hyperacetylation of histone
proteins in the promoter regions of MDR1, BCRP, and
MRP8. Drug-induced apoptosis was impaired in KG-1α
cells treated with phenylbutyrate, resulting in resistance to
daunorubicin, mitoxantrone, etoposide, vinblastine, pacli-
taxel, topotecan, gemcitabine, and 5-fluorouracil [102].
Similarly, the combination of ATRA with depsipeptide
(FK228) induced MDR1 expression in NB4 promyelocytic
leukemia (APL) cells, which normally do not express
MDR1 and are highly sensitive to anthracyclines. Upregu-
lation of MDR1 expression occurred via increased H4 and
Table 1 Clinical trials evaluating DACi in combination with DNMT inhibitors
VPA (d 1–10) +
Decitabine (d 1–10) [93],
VPA (d 5–21)
+ Decitabine
(d 1–10) [94]
VPA + Azacitidine (d 1–
7) + ATRA (d 3–7) [95]
VPA cont. +
Azaciditine
(d 1–7) [96]
Phenylbutyrate (7 d cont.) +
Azacitidine (d1–14 max.) [97]
Patient numbers N=54 N=25 N=53 N=62 N=32
Diagnosis AML (89%), MDS (11%) AML AML (92%) MDS (8%) MDS AML (56%) MDS (44%)
Response (CR,
CRi)
22% 32% 28% 12% 9%
No of previously
untreated patients
11 12 33 na 8
Response of previously
untreated patients
50% 58% 42% na 25%
Survival of responding
patients
median 15 months 3–10 months > 5 months na 8–19+ months
Invest New Drugs (2010) 28 (Suppl 1):S36–S49 S45H3-Lys9 acetylation of the MDR1 promoter, and prevented
doxorubicin-induced growth inhibition and apoptosis in
APL cells. G1 cell-cycle arrest and upregulation of p21
mRNA may have further impaired the induction of
apoptosis of cells in G2 phase. Conversely, initial exposure
to doxorubicin followed by ATRA/FK228 treatment en-
hanced apoptosis [103]. These results indicate that epige-
netic mechanisms leading to a drug resistance phenotype
broader than the “classic multidrug resistance” may be
activated by DACi exposure of AML cells, an effect which
might impair therapeutic efficacy. This highlights the
importance of investigating mechanism-based sequential
therapies in clinical trials that combine DAC inhibitors with
other agents commonly used for treatment of acute
leukemias.
DACi as treatment for acute leukemias and MDS:
a critical appraisal and future perspectives
Despite the profound preclinical activity of DACi against
acute myeloid leukemia cells, their clinical development as
treatment for myeloid malignancies has been less straight-
forward than for several lymphoid malignancies, most
notably cutaneous T cell lymphoma. The to date modest
success in AML and MDS highlights the limitations of our
understanding of the complex interactions between epige-
netic and genetic changes in these malignancies, and the
paucity of our knowledge concerning the biological
function of individual HDAC enzymes and the pleiotropic
cellular effects of DACi. While it has been established that
treatment of leukemic cells with DACi induces cell death,
differentiation and/or cell-cycle arrest, they may also effect
neoplastic growth by influencing the tumor microenviron-
ment, regulating host immune responses or modifying the
properties of normal hematopoietic cells. Thus, the benefi-
cial effect of valproic acid in patients with low risk MDS
may actually be a reflection of the unique ability of VPA to
enhance normal hematopoietic function, whereas patients
with high risk MDS or AML generally do not benefit
because of the insufficient anti-leukemic activity of VPA in
conjunction with the depletion of normal, potentially VPA-
responsive progenitor cells.
In addition, the initial concept that DACi mediate their
biological effects only through the regulation of gene
expression via direct hyperacetylation of histones is no
longer valid, following realisation that DACi acetylate
diverse non-histone proteins, thereby regulating a broad
range of cellular functions independent of transcriptional
mechanisms. It is therefore not surprising that the actions of
DACi are cell-context dependent, and will differ according
to the differential expression and function of the individual
HDACs in a given leukemia. HDAC enzyme expression is
therefore likely to determine differential sensitivity to
various types and dosages of DAC inhibitors, as well as
their toxicity profile.
Limited clinical experience has so far demonstrated the
relative safety of DACi currently in clinical testing, but
adverse effects that become particularly relevant with long-
term use have been noted, some of which, such as fatigue
and diverse gastrointestinal complaints, appear to be class
effects. Moreover, safety aspects will need to be reevaluated
when DACi are combined with other anticancer agents, an
obvious next step in their clinical development given
available evidence that the clinical benefit derived from
epigenetic and chromatin modifiers will be accrued when
they are combined with chemotherapy or other targeted
anti-leukemic agents. The potential of DACi to upregulate
drug efflux pumps is a notable example for potentially
detrimental drug-drug interactions, although there is as yet
no evidence that this is clinically relevant. A rational selection
of appropriate combination partners for DAC inhibitors will
require an improved understanding of the specific epigenetic
and genetic aberrations of each hematologic malignancy,
which will have to be complemented by the identification of
predictive biomarkers. If these challenges can be met, DAC
inhibitors should develop into an important element of novel,
targeted treatment strategies for leukemia.
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